Lowering prescription drug prices is complicated. Just look at insulin.
WASHINGTON The price of a life-saving drug used by some 30 million Americans including 1.3 million in Pennsylvania has nearly tripled since 2002. Average medication costs for the most vulnerable have risen by 600% over the last two decades.
It sounds like a setup for a bipartisan fix in a polarized Washington. Indeed, as Congress has recently advanced broad proposals to lower the cost of prescription drugs, Pennsylvania lawmakers have singled out the soaring cost of insulin, used by diabetics to regulate blood sugar.
But just as those drug pricing overhauls have hit political snags, insulin measures are ensnared in a tangle of bureaucracy, business and pharmaceutical science.
A bill introduced in September by Rep. Mike Kelly, R-Butler, provides a good example. The Market Access for Generic Insulin Competition Act, or MAGIC Act, would help pave the way for a generic form of insulin. Generics are identical copies of drugs that are often sold much cheaper roughly 50% to 80% cheaper, according to government data than their brand-name counterparts.
Read more: https://www.post-gazette.com/business/healthcare-business/2019/10/06/Mike-Kelly-Conor-Lamb-generic-insulin-FDA-prescription-drug-prices/stories/201909180002